3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Interventions
enzalutamide
2
apalutamide
2
Pluvicto
2
Leuprolide
2
Androgen Antagonists
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relugolix
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
luprolide acetate gel depot
1
larotrectinib
1
ipatasertib
1
gallium 68 PSMA-11
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Prostatic Neoplasms
×
Pluvicto
×
Clear all
NCT04689828
2026-03-23
PSMAfore
Novartis
Phase 3
Active not recruiting
469 enrolled
11 charts
1 FDA
NCT03511664
2025-01-13
VISION
Endocyte
Phase 3
Completed
861 enrolled
39 charts
1 FDA